[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
[2] Kirwan JM, Symonds P, Green JA, Tierney J, Collingwood M, Williams CJ. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol. 2003;68(3):217-26.
[3] Collaboration CfCCM-A. Reducing Uncertainties About the Effects of Chemoradiotherapy for Cervical Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 18 Randomized Trials. Journal of Clinical Oncology. 2008;26(35):5802-12.
[4] Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. The Lancet. 2001;358(9284):781-6.
[5] Isohashi F, Yoshioka Y, Mabuchi S, Konishi K, Koizumi M, Takahashi Y, et al. Dose-volume histogram predictors of chronic gastrointestinal complications after radical hysterectomy and postoperative concurrent nedaplatin-based chemoradiation therapy for early-stage cervical cancer. International Journal of Radiation Oncology* Biology* Physics. 2013;85(3):728-34.
[6] Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. International Journal of Radiation Oncology* Biology* Physics. 2002;53(5):1111-6.
[7] Logsdon MD, Eifel PJ. Figo IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. International Journal of Radiation Oncology* Biology* Physics. 1999;43(4):763-75.
[8] Coia L, Won M, Lanciano R, Marcial V, Martz K, Hanks G. The patterns of care outcome study for cancer of the uterine cervix results of the second national practice survey. Cancer. 1990;66(12):2451-6.
[9] John M, Flam M, Caplan R, Rotman M, Quivey J, Steinfeld A, et al. Final results of a phase II chemoradiation protocol for locally advanced cervical cancer: RTOG 85-15. Gynecologic oncology. 1996;61(2):221-6.
[10] Portelance L, Chao KS, Grigsby PW, Bennet H, Low D. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patien ts with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys. 2001;51(1):261-6.
[11] Fenkell L, Kaminsky I, Breen S, Huang S, Van Prooijen M, Ringash J. Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervica l esophagus. Radiother Oncol. 2008;89(3):287-91.
[12] Li S, Zhou Q, Shen L-F, Li H, Li Z-Z, Yang Z, et al. Dosimetric Comparisons of Volumetric Modulated Arc Therapy and Tomotherapy for Early T-Stage Nasopharyngeal Carcinoma. BioMed research international. 2018;2018.
[13] Lee FK, Yip CW, Cheung FC, Leung AK, Chau RM, Ngan RK. Dosimetric difference amongst 3 techniques: TomoTherapy, sliding-window intensity-modulated radiother apy (IMRT), and RapidArc radiotherapy in the treatment of late-stage nasopharyngeal carcinoma (NPC). Med Dosim. 2014;39(1):44-9.
[14] Cozzarini C, Fiorino C, Di Muzio N, Alongi F, Broggi S, Cattaneo M, et al. Significant reduction of acute toxicity following pelvic irradiation with helical tomotherapy in pati ents with localized prostate cancer. Radiother Oncol. 2007;84(2):164-70.
[15] Lin JC, Tsai JT, Chen LJ, Li MH, Liu WH. Compared planning dosimetry of TOMO, VMAT and IMRT in rectal cancer with different simulated position s. Oncotarget. 2017;8(26):42020-9.
[16] Marnitz S, Lukarski D, Köhler C, Wlodarczyk W, Ebert A, Budach V, et al. Helical tomotherapy versus conventional intensity-modulated radiation therapy for primary chemoradiation in cervical cancer patients: an intraindividual comparison. International Journal of Radiation Oncology* Biology* Physics. 2011;81(2):424-30.
[17] Measurements. ICoRUa. Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT). Journal of the ICRU. 2010;10(1):NP.3-NP.
[18] Tan L, Zahra M. Long-term survival and late toxicity after chemoradiotherapy for cervical cancer—the Addenbrooke's experience. Clinical Oncology. 2008;20(5):358-64.
[19] Georg P, Pötter R, Georg D, Lang S, Dimopoulos JC, Sturdza AE, et al. Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy. International Journal of Radiation Oncology* Biology* Physics. 2012;82(2):653-7.
[20] Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU. Radiation dose–volume effects of the urinary bladder. International Journal of Radiation Oncology* Biology* Physics. 2010;76(3):S116-S22.
[21] Engels B, De Ridder M, Tournel K, Sermeus A, De Coninck P, Verellen D, et al. Preoperative helical tomotherapy and megavoltage computed tomography for rectal cancer: impact on the irradiated volume of small bowel. International Journal of Radiation Oncology* Biology* Physics. 2009;74(5):1476-80.
[22] Vernat SS, Ali D, Puyraveau M, Viard R, Lisbona A, Fenoglietto P, et al. Is IMAT the ultimate evolution of conformal radiotherapy? Dosimetric comparison of helical tomotherapy and volumetric modulated arc therapy for oropharyngeal cancer in a planning study. Physica Medica. 2014;30(3):280-5.
[23] Pasquier D, Cavillon F, Lacornerie T, Touzeau C, Tresch E, Lartigau E. A dosimetric comparison of tomotherapy and volumetric modulated arc therapy in the treatment of high-risk prostate cancer with pelvic nodal radiation therapy. International Journal of Radiation Oncology* Biology* Physics. 2013;85(2):549-54.
[24] Xie Y, Bourgeois D, Guo B, Zhang R. Postmastectomy radiotherapy for left-sided breast cancer patients: Comparison of advanced techniques. Medical Dosimetry. 2019.
[25] Xu Y, Deng W, Yang S, Li P, Kong Y, Tian Y, et al. Dosimetric comparison of the helical tomotherapy, volumetric-modulated arc therapy and fixed-field intensity-modulated radiotherapy for stage IIB-IIIB non-small cell lung cancer. Scientific reports. 2017;7(1):14863.
[26] Clivio A, Fogliata A, Franzetti-Pellanda A, Nicolini G, Vanetti E, Wyttenbach R, et al. Volumetric-modulated arc radiotherapy for carcinomas of the anal canal: A treatment planning comparison with fixed field IMRT. Radiotherapy and Oncology. 2009;92(1):118-24.
[27] Vanetti E, Clivio A, Nicolini G, Fogliata A, Ghosh-Laskar S, Agarwal JP, et al. Volumetric modulated arc radiotherapy for carcinomas of the oro-pharynx, hypo-pharynx and larynx: a treatment planning comparison with fixed field IMRT. Radiotherapy and Oncology. 2009;92(1):111-7.